Search

Allergan ruling casts doubt on tribal patent strategy

(Reuters) - A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

Allergan ruling casts doubt on tribal patent strategy
Read More


Bagikan Berita Ini

Related Posts :

0 Response to "Allergan ruling casts doubt on tribal patent strategy"

Posting Komentar

Diberdayakan oleh Blogger.